[2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methane | 166975-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: [2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methane
• 英文别名: 2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-benzo[b]thiophen-6-ol；UNC7084；6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzyl]benzo[b]thiophene；2-(4-Hydroxyphenyl)-3-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-1-benzothiophen-6-ol
• CAS: 166975-45-7
• 化学式: C₂₈H₂₉NO₃S
• 分子量: 459.609
• InChiKey: SGGUFWNHZPVKPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  81.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  双氧水 、 [2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methane 以 甲醇 为溶剂， 生成 [2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methane N-oxide
  参考文献：
  名称：

  Benzothiophenes, formulations containing same, and methods

  摘要：

  这项发明提供了新型苯并噻吩化合物。

  公开号：

  US05731342A1
• 作为产物：
  描述：

  雷洛昔芬 在 三乙基硅烷 、 lithium aluminium tetrahydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 [2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methane
  参考文献：
  名称：

  Discovery and Synthesis of [6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- 2-(4-hydroxyphenyl)]benzo[b]thiophene:  A Novel, Highly Potent, Selective Estrogen Receptor Modulator

  摘要：

  Raloxifene,[2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone hydrochloride (2), is representative of a class of compounds known as selective estrogen receptor modulators (SERMs) that possess estrogen agonist-like actions on bone tissues and serum lipids while displaying potent estrogen antagonist properties in the breast and uterus. As part of ongoing SAR studies with raloxifene, we found that replacement of the carbonyl group with oxygen ([6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b]thiophene hydrochloride, 4c) resulted in a substantial (10-fold) increase in estrogen antagonist potency relative to raloxifene in an in vitro estrogen dependent cell proliferation assay (IC50 = 0.05 nM) in which human breast cancer cells (MCF-7) were utilized. In vivo, 4c potently inhibited the uterine proliferative response to exogenous estrogen in immature rats following both sc and oral dosing (ED50 of 0.006 and 0.25 mg/kg, respectively). In ovariectomized aged rats, 4c produced a significant maximal decrease (45%) in total cholesterol at 1.0 mg/kg (po) and showed a protective effect on bone relative to controls with maximal efficacy at 1.0 mg/kg (po). These data identify 4c as a novel SERM with greater potency to antagonize estrogen in uterine tissue and in human mammary cancer cells compared to raloxifene, tamoxifen or ICI-182,780.

  DOI：

  10.1021/jm970167b

文献信息

• Novel compounds and compositions as protease inhibitors
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：US20020086996A1

  公开（公告）日：2002-07-04

  The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新颖的N-氰甲基酰胺，它们是半胱氨酸蛋白酶抑制剂，以及它们的药用盐和N-氧化物，它们作为治疗剂的用途以及它们的制备方法。
• Novel aryloxy-alkyl-dialkylamines
  申请人：Wyeth

  公开号：EP1777214A2

  公开（公告）日：2007-04-25

  The present invention provides compounds useful in the synthesis of biologically active compounds, and processes for their production, the compounds having the formula: wherein: R1 and R2 are, independently, selected from H; C1-C12 alkyl or C1-C6 perfluorinated alkyl; X represents a leaving group; A is O or S; m is an integer from 1 to 3, preferably 2; R3, R4, R5, and R6 are independently selected from H, halogen, - NO2, alkyl; alkoxy, C1-C6 Perfluorinated alkyl, OH or the C1-C4 esters or alkyl ethers thereof, -CN, -O-R1, -O-Ar, -S-R1, -S-Ar, -SO-R1, -SO-Ar, -SO2-R1, -SO2-Ar, -COR1, -CO-Ar, -CO2-R1, or -CO2-Ar; and Y is selected from a) the moiety: wherein R7 and R8 are independently selected from the group of H, C1-C6 alkyl, or phenyl; or b) an optionally substituted five-, six- or seven-membered saturated, unsaturated or partially unsaturated heterocycle or bicyclic heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C1C4 alkyl)-, -N=, and -S(O)n-.

  本发明提供了在合成生物活性化合物中有用的化合物以及它们的生产方法，所述化合物的化学式为：其中：R1和R2分别选择为H；C1-C12烷基或C1-C6全氟烷基；X代表离去基团；A为O或S；m为1至3的整数，优选为2；R3、R4、R5和R6分别选择为H、卤素、-NO2、烷基、烷氧基、C1-C6全氟烷基、OH或其C1-C4酯或烷基醚、-CN、-O-R1、-O-Ar、-S-R1、-S-Ar、-SO-R1、-SO-Ar、-SO2-R1、-SO2-Ar、-COR1、-CO-Ar、-CO2-R1或-CO2-Ar；Y选择为a)基团：其中R7和R8分别选择为H、C1-C6烷基或苯基；或b)可选取代的五元、六元或七元饱和、不饱和或部分不饱和杂环或双环杂环，其中含有最多两个来自-O-、-NH-、-N（C1-C4烷基）-、-N=和-S（O）n-的杂原子。
• [EN] BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS<br/>[FR] BENZOTHIOPHENES ET COMPOSES ASSOCIES AGONISTES DES OESTROGENES
  申请人：PFIZER INC.

  公开号：WO1995010513A1

  公开（公告）日：1995-04-20

  (EN) Benzothiophenes and related compounds of formula (1), wherein A, B, Z are independently -CH=, -CR4= or =N-; X is -S-, -O-, -NH-, -NR2, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-; -OCH2-, -CH2-S-, -CO-, -SCH2-, -N=CR2- or -R2C=N-; Y is optionally substituted phenyl, alkyl, cycloalkyl, cycloalkenyl, heterocycle or bicyclic ring system; D is -CO-, -CR2R3-, -CONH-, -NHCO-, -CR2(OH)-, -CONR2, NOR1 CH-NO2 N-CN -NR2-CO-, -C-, -C-, -C-; E is a single bond, optionally substituted phenyl, heterocycle; Z1 is -(CH2)p W(CH2)q-, -O(CH2)p CR5R6- or -O(CH2)p W(CH2)q; G is -NR7R8, (a), (b), (c), a 5- or 6-membered saturated, unsaturated or partially unsaturated and optionally substituted heterocycle or a bicyclic amine containing 5 to 12 carbon atoms either bridged or fused and optionally substituted and R is halogen, -NR2R3, -NHCOR2, -NHSO2R2, -CR2R3OH, -CONR2R3, -SO2NR2R3, OH, -OR1, -O-COR1; are estrogen agonists which are useful for treating syndromes and diseases caused by estrogen deficiency.(FR) Benzothiophènes et composés associés de formule (1) agonistes des oestrogènes s'avérant utiles dans le traitement des syndromes et maladies dues aux déficiences en oestrogènes. Dans la formule (I), A, B, Z sont indépendamment -CH=, -CR4= ou =N-; X est -S-, -O-, -NH-, -NR2, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-; -OCH2-, -CH2-S-, -CO-, -SCH2-, -N=CR2- or -R2C=N-; Y est phényle, alkyle, cycloalkyle, cycloalcényle, un hétérocycle, ou un système bicyclique éventuellement substitué; D est -CO-, -CR2R3-, -CONH-, -NHCO-, -CR2(OH)-, -CONR2, NOR1 CH-NO2 N-CN -NR2-CO-, -C-, -C-, -C-; E est une liaison simple, phényle éventuellement substitué, un hétérocycle; Z1 est -(CH2)p W(CH2)q-, -O(CH2)p CR5R6- ou -O(CH2)p W(CH2)q; G est -NR7R8, la formule (a), la formule (b), la formule (c), un hétérocycle à 5 ou 6 chaînons saturé, insaturé ou partiellement saturé et éventuellement substitué, ou une amine bicyclique à 5 à 12 atomes de carbone pontée ou à anneaux condensés et éventuellement substitué, et R est halogène, -NR2R3, -NHCOR2, -NHSO2R2, -CR2R3OH, -CONR2R3, -SO2NR2R3, OH, -OR1, -O-COR1.

  苯并噻吩及其相关化合物的公式（1），其中A，B，Z分别为-CH=，-CR4=或=N-；X为-S-，-O-，-NH-，-NR2，-CH2-CH2-，-CH2-CH2-CH2-，-CH2-O-；-OCH2-，-CH2-S-，-CO-，-SCH2-，-N=CR2-或-R2C=N-；Y为可选取代的苯基，烷基，环烷基，环烯基，杂环或双环系统；D为-CO-，-CR2R3-，-CONH-，-NHCO-，-CR2（OH）-，-CONR2，NOR1 CH-NO2 N-CN -NR2-CO-，-C-，-C-，-C-；E为单键，可选取代的苯基，杂环；Z1为-(CH2)p W(CH2)q-，-O(CH2)p CR5R6-或-O(CH2)p W(CH2)q；G为-NR7R8，（a），（b），（c），一种5或6个成员的饱和，不饱和或部分不饱和且可选取代的杂环或含5至12个碳原子的双环胺，可以是桥接或融合的，R为卤素，-NR2R3，-NHCOR2，-NHSO2R2，-CR2R3OH，-CONR2R3，-SO2NR2R3，OH，-OR1，-O-COR1；是雌激素激动剂，用于治疗由雌激素缺乏引起的综合症和疾病。
• Benzothiophenes, formulations containing same, and methods for their préparation
  申请人：ELI LILLY AND COMPANY

  公开号：EP0791591B1

  公开（公告）日：2001-08-29
• NOVEL ARYLOXY-ALKYL-DIALKYLAMINES
  申请人：Wyeth

  公开号：EP1025077B1

  公开（公告）日：2007-02-28